Developer docs
API playgroundTry for free, no card

Search company profiles

Cure SMC1A Foundation

Full company profile

uuid00yndlo

Namestring
Cure SMC1A Foundation
Legal namestring
SMC1A Foundation
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Cure SMC1A Foundation is a 501(c)(3) nonprofit charitable organization (EIN 84-3406755), legally named SMC1A Foundation, founded in 2021 by parents of children diagnosed with SMC1A-related Developmental and Epileptic Encephalopathy (DEE) — an X-linked genetic disorder characterized by loss-of-function in the SMC1A gene and resulting in intractable seizures and developmental impairment. The foundation operates from San Francisco, California with a European Chapter in Pisa, Italy, and serves two primary constituents: SMC1A patient families (who participate in registries, community programs, and fundraising) and SMC1A researchers (who access de-identified patient data, biosamples, and disease models). Its core product is not a commercial offering but a coordinated suite of research-enablement services: the SMC1A Patient Registry, the Natural History Registry, the Family Contact Registry, and a Community Needs Survey, built on third-party infrastructure including QuestionPro, CoRDS (Coordination of Rare Diseases at Sanford), and Ciitizen (Rare Patient Network).

The foundation's technology layer extends to biosample coordination, facilitating researcher access to patient-derived lymphoblastoid cell lines (LCLs), iPSCs, fibroblasts, brain organoids, and SMC1A knockout mouse models through partnerships with CHOP, Coriell, NIGMS Repository, GemPharmaTech, and Jax Lab. It operates a For Researchers portal and a Foundation-managed Data Manager role focused on transforming registry data into 'decision-grade' assets for global pharmaceutical partners. To date, it has funded two disclosed seed research grants: a $31,000 award to Seattle Children's/UW for molecular etiology work and iPSC/NPC disease modeling, and a $182,935 award to UC Davis for CRISPR-based interventional genetics and gene therapy approaches, the latter co-funded by two patient families.

The business model is philanthropy-only: the foundation generates no commercial revenue, with 100% of donations directed toward SMC1A research and operations. Fundraising is conducted through GoFundMe, PayPal Giving Fund, an eBay storefront, ShopRaise, Bonfire merchandise, employer matching, and social-media-native fundraisers. Go-to-market is community-led, acquiring supporters through Facebook, Twitter/X, LinkedIn, Instagram, YouTube, and TikTok, and converting them via email communications and a gated Facebook parent community. It earned a 2026 Candid Platinum Seal of Transparency, indicating the highest tier of nonprofit accountability. Headcount is reported at 1–10, with all team members being parents of affected children serving in largely volunteer or part-time capacities, including a Medical Advisory Board from UCSF and the Keck School of Medicine of USC.

Short descriptiontext

Cure SMC1A Foundation is a 501(c)(3) nonprofit founded in 2021 by parents of children with SMC1A-related Developmental and Epileptic Encephalopathy, operating patient registries, biosample coordination, and seed research grants to accelerate treatments for this ultra-rare genetic disorder.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease research, patient registries, nonprofit disease advocacy, genetic disorder foundation, epilepsy research funding
Industry3 codes
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAMAG
Biobank & Biospecimen Management LIMS
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Membership Organizations8600
  • Services-Commercial Physical & Biological Research8731
  • Services-Misc Health & Allied Services, Nec8090
Product category
Patient Advocacy and Rare Disease Research Foundation
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Fundraising
TypeGrants Donations
Description

The foundation operates as a 501(c)3 nonprofit that collects donations entirely dedicated to funding SMC1A research studies. Fundraising channels include GoFundMe, PayPal Giving Fund, eBay merchandise sales, ShopRaise, Facebook fundraisers, TikTok fundraisers, Instagram fundraisers, and employer matching programs. All donations are tax-deductible.

smc1a-epilepsy.org
Marketing channels12 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Others, Technology or R&D, Marketing or Sales, Personnel, Operations
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

The SMC1A Foundation operates patient registries (Natural History Registry, Family Contact Registry, Community Survey) built on third-party platforms to collect disease progression, family engagement, and community needs data for SMC1A-DEE research. The foundation funds seed grants for SMC1A gene therapy and precision medicine studies at academic research institutions, and facilitates researcher access to biosamples (cell lines, iPSCs, brain organoids, animal models) and de-identified patient data.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Funded $31,000 seed grant for iPSC and NPC disease modeling study at Seattle Children's/UW
+2 more records
Product overview1 text field

SMC1A Foundation is a patient-led non-profit organization (501(c)3) focused on advancing research for SMC1A-related Developmental and Epileptic Encephalopathy. Rather than a software product company, the Foundation operates a suite of patient registry and community services built on third-party platforms including QuestionPro, CoRDS (Sanford Research), and Ciitizen. The core offerings consist of the SMC1A Patient Registry (collecting baseline disease data), Natural History Registry (longitudinal progression tracking), Family Contact Registry (direct family engagement), and Community Survey (needs assessment). These interconnected registries enable researchers to access de-identified patient data while facilitating the Foundation's mission to accelerate research, build an active research pipeline, and develop meaningful treatments for SMC1A disorders. The Foundation also coordinates bio sample access, maintains a researcher portal, and fosters community connection among affected families worldwide.

Product and service1 record
1SMC1A Patient Registry
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1CoRDS (Coordination of Rare Diseases at Sanford)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Largest centralized international patient registry for all rare diseases. CoRDS collects long-term disease data tracking individuals from childhood to adulthood. SMC1A Foundation participates to advance international patient data collection for research.

smc1a-epilepsy.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform advancing DEE research by collecting and analyzing data extracted from medical records. US families only. Collects records, de-identifies data, and organizes for researcher/pharmaceutical sharing.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

LCLs (Lymphoblastoid Cell Lines) donated to Dr. Ian D. Krantz for biobanking and research distribution.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Antonia Musio leads European research partnership studying dysregulated genes in SMC1A epileptic girls and investigating Ataluren safety/efficacy. Located in Pisa, Italy.

5UW/Seattle Children's (ISCRM)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Xinxian Deng's lab at ISCRM generated iPSCs and disease-mimicking brain organoids from patient cells. Core recipient of foundation seed grants.

smc1a-epilepsy.org
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Biobank providing iPSCs and fibroblast cell lines for SMC1A research upon request.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Distributes conditional SMC1A knockout mouse strain for preclinical disease research.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Provides SMC1A mouse model for research studies on disease aspects.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Network partner for rare epilepsy patient advocacy and research collaboration.

10NIGMS Repository
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research biobank collecting blood/tissue samples and creating cell lines and DNA for scientists. Accepts SMC1A family donations.

smc1a-epilepsy.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kyle Fink, PhD and Julian Halmai, PhD conducting interventional genetics research for SMC1A gene therapy and x-activation approaches. Co-funded by foundation, family Lucia Riestra, and Ricardo Javier Rodriguez.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Federated rare disease data platform that aggregates patient-reported data across multiple disease foundations. SMC1A Foundation's Ciitizen partnership overlaps with RARE-X's mission, making it a broad incumbent in the patient-data layer the foundation depends on.

TypeOthers
Description

Academic center that administers rare disease pilot grants and therapeutic development programs. Comparable as a counterpart funder of seed-stage SMC1A-relevant research and a potential co-funder or partner for the foundation's grant programs.

3SCN1A Foundation
TypeDirect peer
Description

Foundation focused on SCN1A-related disorders, another severe genetic developmental and epileptic encephalopathy. Comparable as a small, parent-led rare epilepsy foundation that funds research and builds patient registries.

TypeBroad incumbent
Description

Network of disease-specific foundations supporting genetic disease research and patient engagement. Comparable as a peer ecosystem organization that connects ultra-rare disease foundations like SMC1A to shared infrastructure and policy.

TypeBroad incumbent
Description

Umbrella advocacy and research-funding organization for the broader rare disease community. Comparable as a macro-level counterpart that competes for philanthropic dollars and provides grant programs (e.g., Rare Disease Day) that rare disease foundations like SMC1A participate in.

TypeDirect peer
Description

Foundation dedicated to Dravet syndrome, a severe genetic developmental and epileptic encephalopathy. Directly comparable to SMC1A Foundation in disease scope (DEE), patient registry infrastructure, and seed grantmaking for genetic epilepsies.

TypeBroad incumbent
Description

Rare disease policy and advocacy foundation that works to accelerate therapeutic development across many individual rare disease communities. Comparable as a policy/advocacy counterpart to SMC1A Foundation's awareness and ICD-10 coding efforts.

TypeDirect peer
Description

Patient-led nonprofit that funded and accelerated the SMA therapeutic pipeline (including Spinraza and Zolgensma). Closely comparable to SMC1A Foundation in model: rare genetic disease, parent-driven, combines patient registry with seed grantmaking for curative therapies.

TypeOthers
Description

Biobank and research institute that provides iPSC and fibroblast cell lines to SMC1A Foundation researchers. Comparable as a critical infrastructure partner that supplies the biosamples the foundation helps distribute.

TypeDirect peer
Description

Foundation for Cornelia de Lange Syndrome, a related cohesinopathy that overlaps with SMC1A mutations. Comparable as a sibling-disease foundation sharing scientific frameworks, researchers, and historically some of the same donor families.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cure SMC1A Foundation

Patient Advocacy and Rare Disease Research Foundationsmc1a-epilepsy.org

Cure SMC1A Foundation is a 501(c)(3) nonprofit founded in 2021 by parents of children with SMC1A-related Developmental and Epileptic Encephalopathy, operating patient registries, biosample coordination, and seed research grants to accelerate treatments for this ultra-rare genetic disorder.

What Cure SMC1A Foundation does

Cure SMC1A Foundation is a 501(c)(3) nonprofit charitable organization (EIN 84-3406755), legally named SMC1A Foundation, founded in 2021 by parents of children diagnosed with SMC1A-related Developmental and Epileptic Encephalopathy (DEE) — an X-linked genetic disorder characterized by loss-of-function in the SMC1A gene and resulting in intractable seizures and developmental impairment. The foundation operates from San Francisco, California with a European Chapter in Pisa, Italy, and serves two primary constituents: SMC1A patient families (who participate in registries, community programs, and fundraising) and SMC1A researchers (who access de-identified patient data, biosamples, and disease models). Its core product is not a commercial offering but a coordinated suite of research-enablement services: the SMC1A Patient Registry, the Natural History Registry, the Family Contact Registry, and a Community Needs Survey, built on third-party infrastructure including QuestionPro, CoRDS (Coordination of Rare Diseases at Sanford), and Ciitizen (Rare Patient Network).

The foundation's technology layer extends to biosample coordination, facilitating researcher access to patient-derived lymphoblastoid cell lines (LCLs), iPSCs, fibroblasts, brain organoids, and SMC1A knockout mouse models through partnerships with CHOP, Coriell, NIGMS Repository, GemPharmaTech, and Jax Lab. It operates a For Researchers portal and a Foundation-managed Data Manager role focused on transforming registry data into 'decision-grade' assets for global pharmaceutical partners. To date, it has funded two disclosed seed research grants: a $31,000 award to Seattle Children's/UW for molecular etiology work and iPSC/NPC disease modeling, and a $182,935 award to UC Davis for CRISPR-based interventional genetics and gene therapy approaches, the latter co-funded by two patient families.

The business model is philanthropy-only: the foundation generates no commercial revenue, with 100% of donations directed toward SMC1A research and operations. Fundraising is conducted through GoFundMe, PayPal Giving Fund, an eBay storefront, ShopRaise, Bonfire merchandise, employer matching, and social-media-native fundraisers. Go-to-market is community-led, acquiring supporters through Facebook, Twitter/X, LinkedIn, Instagram, YouTube, and TikTok, and converting them via email communications and a gated Facebook parent community. It earned a 2026 Candid Platinum Seal of Transparency, indicating the highest tier of nonprofit accountability. Headcount is reported at 1–10, with all team members being parents of affected children serving in largely volunteer or part-time capacities, including a Medical Advisory Board from UCSF and the Keck School of Medicine of USC.

Cure SMC1A Foundation firmographics

Firmographics
Name
Cure SMC1A Foundation
Legal name
SMC1A Foundation
Website
https://smc1a-epilepsy.org
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Cure SMC1A Foundation is a 501(c)(3) nonprofit founded in 2021 by parents of children with SMC1A-related Developmental and Epileptic Encephalopathy, operating patient registries, biosample coordination, and seed research grants to accelerate treatments for this ultra-rare genetic disorder.
Ownership category
akta.pro rank

Cure SMC1A Foundation industry classification

Industry
Product category
Patient Advocacy and Rare Disease Research Foundation
NAICS
Voluntary Health Organizations (813212), Scientific Research and Development Services (5417)
SIC
Services-Membership Organizations (8600), Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLACAHAH
Patient Registries & Chronic Disease Registry Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAMAG
Biobank & Biospecimen Management LIMS
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • Rare disease research
  • Patient registries
  • Nonprofit disease advocacy
  • Genetic disorder foundation
  • Epilepsy research funding

Where Cure SMC1A Foundation is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cure SMC1A Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Others, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

  1. Donations and Fundraising: The foundation operates as a 501(c)3 nonprofit that collects donations entirely dedicated to funding SMC1A research studies. Fundraising channels include GoFundMe, PayPal Giving Fund, eBay merchandise sales, ShopRaise, Facebook fundraisers, TikTok fundraisers, Instagram fundraisers, and employer matching programs. All donations are tax-deductible.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels12 records

Cure SMC1A Foundation product offering

Product offering

Core offering

The SMC1A Foundation operates patient registries (Natural History Registry, Family Contact Registry, Community Survey) built on third-party platforms to collect disease progression, family engagement, and community needs data for SMC1A-DEE research. The foundation funds seed grants for SMC1A gene therapy and precision medicine studies at academic research institutions, and facilitates researcher access to biosamples (cell lines, iPSCs, brain organoids, animal models) and de-identified patient data.

Product overview

SMC1A Foundation is a patient-led non-profit organization (501(c)3) focused on advancing research for SMC1A-related Developmental and Epileptic Encephalopathy. Rather than a software product company, the Foundation operates a suite of patient registry and community services built on third-party platforms including QuestionPro, CoRDS (Sanford Research), and Ciitizen. The core offerings consist of the SMC1A Patient Registry (collecting baseline disease data), Natural History Registry (longitudinal progression tracking), Family Contact Registry (direct family engagement), and Community Survey (needs assessment). These interconnected registries enable researchers to access de-identified patient data while facilitating the Foundation's mission to accelerate research, build an active research pipeline, and develop meaningful treatments for SMC1A disorders. The Foundation also coordinates bio sample access, maintains a researcher portal, and fosters community connection among affected families worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • SMC1A Patient Registry

Quantifiable outcome

  • Funded $31,000 seed grant for iPSC and NPC disease modeling study at Seattle Children's/UW
  • +2 more outcomes

Companies that use Cure SMC1A Foundation

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Cure SMC1A Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cure SMC1A Foundation partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and supporting.

  • CoRDS (Coordination of Rare Diseases at Sanford)coreStrategic or Co-development PartnerLargest centralized international patient registry for all rare diseases. CoRDS collects long-term disease data tracking individuals from childhood to adulthood. SMC1A Foundation participates to advance international patient data collection for research.
  • Ciitizen (Citizen Health)coreStrategic or Co-development PartnerPlatform advancing DEE research by collecting and analyzing data extracted from medical records. US families only. Collects records, de-identifies data, and organizes for researcher/pharmaceutical sharing.
  • CHOP (Children's Hospital of Philadelphia)supportingStrategic or Co-development PartnerLCLs (Lymphoblastoid Cell Lines) donated to Dr. Ian D. Krantz for biobanking and research distribution.
  • CNR Italy (Institute of Technologies Biomedical, National Research Council)coreStrategic or Co-development PartnerDr. Antonia Musio leads European research partnership studying dysregulated genes in SMC1A epileptic girls and investigating Ataluren safety/efficacy. Located in Pisa, Italy.
  • UW/Seattle Children's (ISCRM)coreStrategic or Co-development PartnerDr. Xinxian Deng's lab at ISCRM generated iPSCs and disease-mimicking brain organoids from patient cells. Core recipient of foundation seed grants.
  • Coriell InstitutesupportingStrategic or Co-development PartnerBiobank providing iPSCs and fibroblast cell lines for SMC1A research upon request.
  • GemPharmaTechsupportingStrategic or Co-development PartnerDistributes conditional SMC1A knockout mouse strain for preclinical disease research.
  • Jax LabsupportingStrategic or Co-development PartnerProvides SMC1A mouse model for research studies on disease aspects.
  • Rare Epilepsy NetworksupportingStrategic or Co-development PartnerNetwork partner for rare epilepsy patient advocacy and research collaboration.
  • NIGMS RepositorysupportingStrategic or Co-development PartnerResearch biobank collecting blood/tissue samples and creating cell lines and DNA for scientists. Accepts SMC1A family donations.
  • UC Davis Regenerative Medicine Stem Cell ProgramcoreStrategic or Co-development PartnerKyle Fink, PhD and Julian Halmai, PhD conducting interventional genetics research for SMC1A gene therapy and x-activation approaches. Co-funded by foundation, family Lucia Riestra, and Ricardo Javier Rodriguez.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Cure SMC1A Foundation competitors and assessment

Company assessment

Broad incumbents

  • RARE-X: Federated rare disease data platform that aggregates patient-reported data across multiple disease foundations. SMC1A Foundation's Ciitizen partnership overlaps with RARE-X's mission, making it a broad incumbent in the patient-data layer the foundation depends on.
  • Genetic Alliance: Network of disease-specific foundations supporting genetic disease research and patient engagement. Comparable as a peer ecosystem organization that connects ultra-rare disease foundations like SMC1A to shared infrastructure and policy.
  • National Organization for Rare Disorders (NORD): Umbrella advocacy and research-funding organization for the broader rare disease community. Comparable as a macro-level counterpart that competes for philanthropic dollars and provides grant programs (e.g., Rare Disease Day) that rare disease foundations like SMC1A participate in.
  • EveryLife Foundation for Rare Diseases: Rare disease policy and advocacy foundation that works to accelerate therapeutic development across many individual rare disease communities. Comparable as a policy/advocacy counterpart to SMC1A Foundation's awareness and ICD-10 coding efforts.

Others

  • Orphan Disease Center (University of Pennsylvania): Academic center that administers rare disease pilot grants and therapeutic development programs. Comparable as a counterpart funder of seed-stage SMC1A-relevant research and a potential co-funder or partner for the foundation's grant programs.
  • Coriell Institute for Medical Research: Biobank and research institute that provides iPSC and fibroblast cell lines to SMC1A Foundation researchers. Comparable as a critical infrastructure partner that supplies the biosamples the foundation helps distribute.

Direct peers

  • SCN1A Foundation: Foundation focused on SCN1A-related disorders, another severe genetic developmental and epileptic encephalopathy. Comparable as a small, parent-led rare epilepsy foundation that funds research and builds patient registries.
  • Dravet Syndrome Foundation: Foundation dedicated to Dravet syndrome, a severe genetic developmental and epileptic encephalopathy. Directly comparable to SMC1A Foundation in disease scope (DEE), patient registry infrastructure, and seed grantmaking for genetic epilepsies.
  • Cure SMA: Patient-led nonprofit that funded and accelerated the SMA therapeutic pipeline (including Spinraza and Zolgensma). Closely comparable to SMC1A Foundation in model: rare genetic disease, parent-driven, combines patient registry with seed grantmaking for curative therapies.
  • CdLS Foundation: Foundation for Cornelia de Lange Syndrome, a related cohesinopathy that overlaps with SMC1A mutations. Comparable as a sibling-disease foundation sharing scientific frameworks, researchers, and historically some of the same donor families.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cure SMC1A Foundation social profiles

Digital presence

Cure SMC1A Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cure SMC1A Foundation leadership team

Management profile

Number of profiles

Profiles9 records

Cure SMC1A Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cure SMC1A Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cure SMC1A Foundation

What does Cure SMC1A Foundation do?

The SMC1A Foundation operates patient registries (Natural History Registry, Family Contact Registry, Community Survey) built on third-party platforms to collect disease progression, family engagement, and community needs data for SMC1A-DEE research. The foundation funds seed grants for SMC1A gene therapy and precision medicine studies at academic research institutions, and facilitates researcher access to biosamples (cell lines, iPSCs, brain organoids, animal models) and de-identified patient data.

Is Cure SMC1A Foundation a public or private company?

Cure SMC1A Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Cure SMC1A Foundation founded?

Cure SMC1A Foundation was founded in 2021. It employs 1 to 10 people.

Where is Cure SMC1A Foundation based?

Cure SMC1A Foundation is headquartered in San Francisco, United States, in the North America region.

How does Cure SMC1A Foundation make money?

One revenue line is on record: donations and Fundraising.

Who are Cure SMC1A Foundation's main competitors?

Broad incumbents on record are RARE-X, Genetic Alliance, National Organization for Rare Disorders (NORD) and EveryLife Foundation for Rare Diseases. Others are Orphan Disease Center (University of Pennsylvania) and Coriell Institute for Medical Research. Direct peers are SCN1A Foundation, Dravet Syndrome Foundation, Cure SMA and CdLS Foundation.

Does Cure SMC1A Foundation have an API?

No public API is recorded for Cure SMC1A Foundation.

What industry is Cure SMC1A Foundation in?

Cure SMC1A Foundation's product category is Patient Advocacy and Rare Disease Research Foundation. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of HLACAHAH, Patient Registries & Chronic Disease Registry Analytics. Its NAICS code is 813212 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales